Neurocrine Biosciences
NBIX
#1344
Rank
A$24.21 B
Marketcap
A$240.84
Share price
2.86%
Change (1 day)
22.56%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : A$2.17 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are A$2.17 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31A$2.05 B13.38%
2024-12-31A$1.81 B21.31%
2023-12-31A$1.49 B54.06%
2022-12-31A$0.97 B0.8%
2021-12-31A$0.96 B21.75%
2020-12-31A$0.79 B-17.19%
2019-12-31A$0.95 B31.39%
2018-12-31A$0.72 B27.47%
2017-12-31A$0.57 B719.15%
2016-12-31A$69.65 M0.82%
2015-12-31A$69.08 M64.68%
2014-12-31A$41.95 M9.21%
2013-12-31A$38.41 M-4.05%
2012-12-31A$40.03 M-47.56%
2011-12-31A$76.35 M-37.99%
2010-12-31A$0.12 B65.43%
2009-12-31A$74.43 M-35.49%
2008-12-31A$0.11 B-36.13%
2007-12-31A$0.18 B90%
2006-12-31A$95.09 M-25.2%
2005-12-31A$0.12 B-21.54%
2004-12-31A$0.16 B-26.49%
2003-12-31A$0.22 B193.68%
2002-12-31A$75.05 M6.53%
2001-12-31A$70.45 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
A$169.99 B 7,720.52%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$207.50 B 9,445.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$123.82 B 5,596.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.19 B-44.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$63.55 M-97.08%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$1.24 B-42.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A$11.91 M-99.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$14.32 B 559.10%๐Ÿ‡ฌ๐Ÿ‡ง UK